ÂÜÀòÂÒÂ×

Dr. Fjällskog has over 30 years of experience in clinical oncology, translational research, and drug development. She joined Faron from Sensei Biotherapeutics (SNSE), a Nasdaq-listed immuno-oncology company. As Chief Medical Officer at Sensei, she was responsible for leading clinical and development strategy and operations. She also played a key role in Sensei’s successful $152 million IPO, which closed in February 2021.

Previously, she served as Vice President, Clinical Development at Merus (MRUS) and Infinity Pharmaceuticals (INFI) where she led the development of multiple small molecules and immuno-oncology clinical programs. She was formerly Global Clinical Program Leader at the Novartis Institute for Biomedical Research where she led the global development of oncology treatments targeting CDK4/6, BCL-2, PD-1, CSF-1, and CD73.

Dr. Fjällskog holds both a Ph.D. and an M.D. from Uppsala University, Sweden where she currently serves as an Associate Professor of Oncology Dr. Fjällskog also serves on the Board of Biovica, a Swedish biotech company focused on predicting the efficacy of cancer therapies via novel blood-based diagnostics and Lytix Biopharma, a clinical-stage biotech developing novel cancer immunotherapies based on pioneering research in host defense peptides.